Specialties
Dr. Chunrong Tong
Head of the Immunotherapy and Targeted Therapy Department, Director of Scientific Research
Diseases & Conditions Treated
Specializes in the integrated diagnosis (combining clinical history with various laboratory diagnostic techniques) and comprehensive treatment (chemotherapy, immunotherapy, targeted therapy, etc.) of …
Dr. Tong Wu
Medical Director, Head of Hematopoietic Stem Cell Transplantation Department, Member of the Academic Committee of the Asia-Pacific Bone Marrow Transplantation Society
Diseases & Conditions Treated
Specializes in selecting transplantation methods, managing severe transplant-related graft-versus-host disease (GVHD) and infections, transplanting for refractory/relapsed leukemia and preventing post…
Dr. Yonghong Zhang
Head of the Department of Pediatric Lymphoma, leading the pediatric lymphoma and pediatric hematology disciplines.
Diseases & Conditions Treated
From 1999 to 2004, made multiple visits as a visiting scholar to the St. Jude Children's Research Hospital in the United States and the Pediatric Oncology Center at Prince of Wales Hospital, Chinese U…
Dr. Xiaoyan Ke
Chief Consultant, Head of the Adult Lymphoma Department, Doctoral Supervisor.
Diseases & Conditions Treated
Specializes in the standardized treatment of lymphoma; molecular biological diagnosis of malignant hematological diseases and lymphomas and monitoring of minimal residual disease; research related to …
Dr. Lugui Qiu
Chief Scientist at GoBroad Healthcare Group Myeloma Research Institute.
Diseases & Conditions Treated
Dr. Zifen Gao
Top-level expert at the Gobroad Healthcare Group's Lymphoma Research Institute.
Diseases & Conditions Treated
Engaged in pathology teaching, medical care, and scientific research for over 40 years. In recent years, dedicated to the internationalization of hematopathology diagnostic patterns, actively engagin…
Acdemic Discipline
General Hematology
Dr. Chunrong Tong
Head of the Immunotherapy and Targeted Therapy Department, Director of Scientific Research
Diseases & Conditions Treated
Specializes in the integrated diagnosis (combining clinical history with various laboratory diagnostic techniques) and comprehensive treatment (chemotherapy, immunotherapy, targeted therapy, etc.) of …
Hematopoietic stem cell transplantation
Dr. Tong Wu
Medical Director, Head of Hematopoietic Stem Cell Transplantation Department, Member of the Academic Committee of the Asia-Pacific Bone Marrow Transplantation Society
Diseases & Conditions Treated
Specializes in selecting transplantation methods, managing severe transplant-related graft-versus-host disease (GVHD) and infections, transplanting for refractory/relapsed leukemia and preventing post…
Pediatric Lymphoma
Dr. Yonghong Zhang
Head of the Department of Pediatric Lymphoma, leading the pediatric lymphoma and pediatric hematology disciplines.
Diseases & Conditions Treated
From 1999 to 2004, made multiple visits as a visiting scholar to the St. Jude Children's Research Hospital in the United States and the Pediatric Oncology Center at Prince of Wales Hospital, Chinese U…
Lymphoma and myeloma
Dr. Xiaoyan Ke
Chief Consultant, Head of the Adult Lymphoma Department, Doctoral Supervisor.
Diseases & Conditions Treated
Specializes in the standardized treatment of lymphoma; molecular biological diagnosis of malignant hematological diseases and lymphomas and monitoring of minimal residual disease; research related to …
Myeloma and Lymphoma
Dr. Lugui Qiu
Chief Scientist at GoBroad Healthcare Group Myeloma Research Institute.
Diseases & Conditions Treated
Integrated Diagnostic Center
Dr. Zifen Gao
Top-level expert at the Gobroad Healthcare Group's Lymphoma Research Institute.
Diseases & Conditions Treated
Engaged in pathology teaching, medical care, and scientific research for over 40 years. In recent years, dedicated to the internationalization of hematopathology diagnostic patterns, actively engagin…
Patient Story
"I would like to express my heartfelt gratitude to the exceptional team of doctors, nurses, and administrative staff at Beijing Goboraod Boren Hospital. Their constant support and assistance during my son's CAR-T cell therapy treatment were invaluable to us."
Find out more"I am deeply grateful for the excellent and professional medical team at Boren Hospital for their treatment and care of my grandmother. During her treatment period, the hospital provided an outstanding living service team to organize daily life and an excellent medical staff team for medical procedures. The treatment results exceeded all expectations. Thank you very much, Boren Hospital."
Find out more"I sincerely appreciate the outstanding medical team at Beijing GoBroad Boren Hospital. Throughout the entire process of my brother receiving CAR-T cell therapy, the considerate services and high-quality medical care provided by the hospital left a deep impression on us. They not only offered professional treatment but also provided our family with emotional support, filling us with confidence in facing the disease. The hospital environment is warm, creating a homely feeling. "
Find out moreCAR-T Advantage
GoBroad Medical Institute of Hematology (Beijing Center),Beijing GoBroad Boren Hospital's CAR-T therapy is renowned for its comprehensive target selection, covering a wide range of hematologic malignancy targets, including single targets like CD19, CD20, CD22, CD7, CD5, BCMA, GPRC5D, as well as dual-target and triple-target CAR-T therapies. This offers targeted treatment plans for various leukemias, lymphomas, and myelomas. The comprehensiveness of these targets ensures the broad applicability and personalization of the treatment, bringing new hope to patients with different types of hematologic malignancies.In terms of efficacy, our CAR-T therapy has achieved significant clinical success. From June 2017 to March 2024, a total of 4000 CAR-T clinical research cases have been completed, with a complete remission rate of over 80%. For example, the complete remission rate for R/R B-ALL patients treated with CD19 CAR-T exceeds 90%. Similarly, treatments using CD7 CAR-T and CD5 CAR-T for T-cell lymphoma patients have also shown good efficacy, improving patients' quality of life and significantly extending survival periods. Additionally, for B-cell lymphomas such as refractory/relapsed diffuse large B-cell lymphoma (DLBCL), our CAR-T therapy has also achieved excellent efficacy, with a high propor…
Find out more
